tldrdailynews.com logo
Tag

Zepbound

All articles tagged with #zepbound

FDA Approves Higher-Dose Wegovy to Narrow Gap with Zepbound
business23 days ago

FDA Approves Higher-Dose Wegovy to Narrow Gap with Zepbound

The FDA approved Novo Nordisk’s higher-dose Wegovy (7.2 mg) to improve weight loss outcomes, with phase 3 data showing about 20.7% average weight loss over 72 weeks; Novo plans an April launch to better compete with Eli Lilly’s Zepbound, which has demonstrated higher efficacy. A separate trial in obesity with Type 2 diabetes showed 14.1% weight loss, and the approval comes as the FDA pilots a faster review program for priority GLP-1 medications.

via CNBC|
#business#fda#novo-nordisk
Lilly warns of unknown safety risks in tirzepatide-B12 compounded drugs
health1 month ago

Lilly warns of unknown safety risks in tirzepatide-B12 compounded drugs

Eli Lilly issued a public warning about potential patient safety risks from compounded tirzepatide mixed with vitamin B12, including a newly identified impurity with unknown short- and long-term effects. The company says these compounded tirzepatide-B12 products lack safety monitoring and adverse-event reporting, has alerted the FDA, and urges patients to discuss alternatives with their physicians. Lilly also cautions about broader safety issues and contaminants in other unregulated tirzepatide knockoffs and calls for regulator action to curb mass compounding in favor of FDA-approved therapies like Mounjaro and Zepbound.

via Eli Lilly|
#compounded-drugs#fda#health
Lilly Launches Employer Connect to Expand Employer Coverage for Obesity Drugs
business1 month ago

Lilly Launches Employer Connect to Expand Employer Coverage for Obesity Drugs

Eli Lilly unveils Employer Connect to help employers cover obesity medicines by connecting them with 15+ program administrators and offering a net price of $449 per month for a new Zepbound dose, aiming to lower employee out-of-pocket costs while giving employers design flexibility and price visibility; the move comes as Medicare coverage for these drugs is set to expand later this year and some firms may opt in gradually.

via CNBC|
#business#employer-coverage#glp-1
CagriSema lags Zepbound as Novo Nordisk presses toward FDA decision
business1 month ago

CagriSema lags Zepbound as Novo Nordisk presses toward FDA decision

Novo Nordisk’s obesity drug CagriSema delivered slightly less weight loss than Lilly’s Zepbound in an 84-week phase 3 trial, raising questions about its market potential ahead of a late-2026 FDA decision and a possible 2027 launch. Novo defends the drug’s efficacy and points to additional trials (REDEFINE 11 and a higher-dose study) while analysts warn it may struggle to gain share from Zepbound, signaling potential reliance on future deals to bolster its pipeline.

via CNBC|
#business#cagrisema#novo-nordisk
Lilly's weight‑loss drugs drive strong quarter, lift 2026 outlook and stock
business2 months ago

Lilly's weight‑loss drugs drive strong quarter, lift 2026 outlook and stock

Eli Lilly posted 4Q25 sales of $19.3 billion, up 43%, driven by Zepbound at $4.3 billion (up 123%) and Mounjaro at $7.4 billion (up 110%), beating estimates with $11.7 billion from the two drugs. The company guided 2026 revenue of $80–83 billion and adjusted EPS of $33.50–$35.00, signaling ongoing growth even as Novo Nordisk anticipates a 5–13% 2026 decline. Lilly also struck a most‑favored‑nations deal for discounts via TrumpRx, and its stock rose in premarket trading.

via MarketWatch|
#business#earnings#lilly
business2 months ago

Lilly fuels growth with Q4 2025 results, raises 2026 outlook to $80–83B

Eli Lilly reported Q4 2025 revenue of $19.3B, up 43% y/y, with GAAP EPS of $7.39 and non-GAAP EPS of $7.54, driven by strong demand for Mounjaro and Zepbound. The company highlighted regulatory progress (FDA approval of Kwikpen for tirzepatide and expanded Jaypirca indication) and a 2026 revenue guidance of $80–$83B with non-GAAP EPS of $33.50–$35.00, along with ongoing obesity/diabetes pipeline developments and a U.S. government agreement to expand access to obesity medicines.

via Eli Lilly|
#2026-guidance#business#lilly
Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook
business2 months ago

Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook

Eli Lilly beat Q4 estimates with adjusted EPS of $7.54 and revenue of $19.29B (up 43%), and issued 2026 guidance of $80-83B in revenue and $33.50-35 in EPS, powered by robust GLP-1 demand for Zepbound and Mounjaro. U.S. sales reached $12.9B with volume up about 50% while prices moderated. Lilly faces competition from Novo Nordisk and highlighted pricing steps under a 2026 deal with Medicare/Medicaid and a direct-to-consumer TrumpRx platform, with most pricing moves expected early in 2026 and volume growth ramping in the second half. The company is also pursuing an oral weight-loss drug, orforglipron, later this year.

via CNBC|
#business#earnings#eli-lilly
Novo’s New Wegovy Pill Surges Out of the Gate
business2 months ago

Novo’s New Wegovy Pill Surges Out of the Gate

Novo Nordisk’s oral Wegovy is off to a strong start, with Week 2 prescriptions around 18,000–20,000, reportedly higher than the initial weeks of injectable Wegovy and Lilly’s Zepbound. Analysts say the rapid uptake could help Novo regain obesity market share as it faces competition from Lilly’s orforglipron and Zepbound’s dominance; the pill is priced at $149 per 1.5 mg dose (cash) with insured patients potentially paying as low as $25 per month, and Novo’s stock has risen about 20% this year in response.

via Fierce Pharma|
#business#novo-nordisk#obesity
Half of GLP-1 users abandon injections as weight loss returns prompt new maintenance options
personal-finance2 months ago

Half of GLP-1 users abandon injections as weight loss returns prompt new maintenance options

New research finds about 50% of people who stop GLP-1 weight-loss drugs Wegovy or Zepbound regain all the weight they lost within two years, with cost and gastrointestinal side effects driving discontinuation. As patients seek durable results, doctors point to a mix of options—from bariatric procedures and endoscopic sleeve gastroplasty to new oral GLP-1 pills like Wegovy’s pill and Lilly’s orforglipron—though real-world adherence and insurance coverage remain uncertain.

via MarketWatch|
#glp-1#obesity#personal-finance
Eli Lilly reduces Zepbound weight-loss drug prices amid industry trend
business4 months ago

Eli Lilly reduces Zepbound weight-loss drug prices amid industry trend

Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.

via CNBC|
#business#eli-lilly#pharmaceuticals